| Name | Title | Contact Details |
|---|
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, VDAs are potentially complementary with anti-angiogenic drugs and chemotherapeutic agents. OXiGENE has ongoing VDA drug development programs and is committed to advancing the science of VDAs and their potential as innovative therapies to address unmet medical needs.
Abilities Foundation of Nova Scotia is a Halifax, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AMR Medical /AR Technologies Company (ARTCO) is a Fresno, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Since 1990, Independence Medical has been one of the nation's leading wholesale medical supply distributors. Being a privately held company, we are responsive to your ever-changing needs and flexible in developing the best services for your company. You
Medacta International is a Swiss company developing, manufacturing and distributing orthopaedic and neurosurgical medical devices worldwide. Founded in 1999 with a vision to create a better patient experience for people needing joint and spine treatment, Medacta specializes in highly innovative minimally-invasive, personalized approaches designed to bring renewed hope and optimism to patients. Medacta is a recognized leader in Hip Replacement with its proprietary AMIS® (Anterior Minimally Invasive Surgery) product offerings and in Knee Replacement via MyKnee® Patient Matched 3-D printing technology. At the 2014 North American Spine Society (NASS) Annual Meeting, Medacta`s new MySpine® Patient Matched product was awarded "Best New Technology - Posterior Thoracolumbar Spine Treatments".